Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

EP: 1.Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

EP: 2.Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

EP: 3.Dr. Anees Chagpar Named 2021 ASCO Fellow

EP: 4.Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences

EP: 5.Yale Research to be Presented at 2021 ASCO Annual Meeting

EP: 6.Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

EP: 7.Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center

EP: 8.Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award

EP: 9.Yale Cancer Center Perspective Highlights New Advances for NSCLC

EP: 10.Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

EP: 11.Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

EP: 12.Dr. Lustberg Discusses Ongoing Research in Breast Cancer

EP: 13.Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

EP: 14.Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

EP: 15.Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital

EP: 16.Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

EP: 17.Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma

EP: 18.Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

EP: 19.Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

EP: 20.Immunotherapy Advances Drive Progress in Lung Cancer Treatment

EP: 21.Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center

EP: 22.Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers

EP: 23.Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

Now Viewing

EP: 24.Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

EP: 25.Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

EP: 26.Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

EP: 27.Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

EP: 28.Expert Insights on First-line Treatment Strategies in SCLC

EP: 29.Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

EP: 30.ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

EP: 31.Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

EP: 32.Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

EP: 33.Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

EP: 34.Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

EP: 35.LAGOON and IMFORTE Trials: Data Updates and Expert Insights

EP: 36.2L Dosing Considerations and Management Strategies for SCLC

EP: 37.Novel Treatment Approaches for SCLC and Future Perspectives

Daniel P. Petrylak, MD, professor of medicine and urology, coleader, Cancer Signaling Networks, Yale Cancer Center, discusses the rationale for of the phase 1b/2 EV-103 trial (NCT03288545) in patients with muscle-invasive bladder cancer (MIBC).

The EV-103 trial focused on patients with MIBC who were not eligible to receive cisplatin neoadjuvant chemotherapy, Petrylak says. Cisplatin-based chemotherapy is the current standard of care for those eligible in the patient population, and approximately one-third of those patients will achieve a pathological complete response, Petrylak adds. Cisplatin has been demonstrated to improve survival when compared with cystectomy alone in those with locally advanced muscle invasive disease, Petrylak explains.

The EV-103 study identified cisplatin-ineligible patients who predominately presented with poor renal function, Petrylak notes. They were administered enfortumab vedotin-ejfv (Padcev) for 3 cycles. Moreover, the cycles were adjusted so patients received the therapy on days 1 and 8, rather than days 1, 8, and 15, which is approved the approved regimen for metastatic patients, Petrylak concludes.